Retatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — making it the most mechanistically comprehensive weight management peptide in clinical development. Phase 2 trials have shown weight loss exceeding 24% of body weight, surpassing both Semaglutide and Tirzepatide.
Quick facts
- Half-life
- ~6 days
- Administration
- Subcutaneous injection (weekly)
- Primary use
- Weight management, metabolic health
How it works
By activating all three receptors — GLP-1 (appetite and insulin), GIP (insulin and fat metabolism), and glucagon (energy expenditure and lipolysis) — Retatrutide produces a broader metabolic effect than dual agonists. The glucagon component increases energy expenditure, which is absent in GLP-1 and GIP/GLP-1 agents.
Reported benefits
- Superior weight loss in Phase 2 trials — up to 24% body weight reduction
- Triple receptor mechanism — GLP-1, GIP, and glucagon
- Increased energy expenditure via glucagon receptor activation
- Improved metabolic markers — glucose, lipids, and liver fat
Typical dosing protocol
Dosing
Phase 2 trials used 1–12 mg/week, titrated over several months. Not yet commercially available.
Cycle length
Long-term / ongoing under medical supervision
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Currently in Phase 3 clinical trials — not yet approved anywhere. Not available for human use in the UK outside of clinical trials. Side effects in trials include nausea, vomiting, and diarrhoea. Consult a healthcare professional before use.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.